Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With Ruxolitinib
Sponsor: Samus Therapeutics, Inc.
Terminated
Samus Therapeutics company closure
Other terminated trials from Samus Therapeutics, Inc.
- Alzheimer Disease · Phase PHASE2 · Nov 2022
- Glioblastoma Surgery · Phase PHASE1 · Nov 2022
- Myelofibrosis · Phase PHASE1 · Mar 2020
- Alzheimer's Disease · Phase PHASE1 · Dec 2019
More terminations from Samus Therapeutics, Inc.
Listed as NCT03935555, this PHASE1 trial focuses on Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Post-Polycythemia Vera Myelofibrosis (Post-PV MF) and remains terminated or withdrawn. Sponsored by Samus Therapeutics, Inc., it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Oct 2021 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2019 — Nov 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Samus Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .